• Farrow

Tracking

Search

Navigation

Update on extension of Covid-19 Section 301 Exclusions

Home News Update on extension of Covid-19 Section 301 Exclusions

In prior notices, the U.S. Trade Representative modified the action in the Section 301 investigation of China’s acts, policies, and practices related to technology transfer, intellectual property, and innovation by excluding from additional duties certain medical-care products needed to address the COVID-19 pandemic. The 99 exclusions for medical care products to address COVID-19 were published on December 29, 2020, and
are scheduled to expire on November 14, 2021. On August 27, 2021, USTR requested comments on whether to extend the COVID exclusions. This notice announces the U.S. Trade Representative’s determination to provide a 16-day transition period for all COVID exclusions (through November 30, 2021), and to extend 81 of the COVID exclusions for an additional 6 months.

Background:

In the course of this investigation the U.S. Trade Representative imposed additional duties on products of China in four tranches. See 83 FR 28719 (June 20, 2018); 83 FR 40823 (August 16, 2018); 83 FR 47974 (September 21, 2018), as modified by 83 FR 49153 (September 28, 2018); and 84 FR 43304 (August 20, 2019), as modified by 84 FR 69447 (December 18, 2019) and 85 FR 3741 (January 22, 2020).

For each tranche, the U.S. Trade Representative established a process by which U.S. stakeholders could request the exclusion of particular products subject to the action. The U.S. Trade Representative later established a process by which U.S. stakeholders could request the extension of particular exclusions. Additionally, on March 25, 2020, the U.S. Trade Representative requested public comments on possible further modifications
to remove Section 301 duties from medical-care products to address the COVID-19 pandemic. 85 FR 16987.

On December 29, 2020, USTR announced the extension of 80 product exclusions on medical-care and/or COVID response products; further modifications in the form of 19 product exclusions to remove Section 301 duties from additional medical-care and/or COVID response products; and that USTR might consider further extensions and/or modifications as appropriate. See 85 FR 85831 (the December 29 notice). On March 10,
2021, USTR announced the extension of these 99 exclusions until September 30, 2021 and that USTR might consider further extensions and/or modifications as appropriate. 86 3 FR 13785. On August 27, 2021, USTR published a notice requesting public comments on whether any of these exclusions should be further extended for up to six months. 86 FR 48280 (the August 27 notice). The August 27 notice stated that USTR would evaluate each exclusion on a case-by-case basis and the evaluation would examine whether the exclusion remains appropriate in light of recent developments including the spread of the Delta variant in the United States and increased domestic production of certain products, and taking account of the overall impact of these exclusions on the goal of obtaining the elimination of China’s acts, policies, and practices covered in this Section 301 investigation.

For full notice, click here.

Source: U.S. Trade Representative

Back to Farrow News

Grow your business with our logistics solutions

Get the expert support and service needed to comply with shipping regulations, optimize your supply chain and more.

White Farrow icon

Your international trade experts are here to help.

Transporting your goods across borders? Get in touch and a Farrow representative will reach out shortly.

Request a Quote
White Farrow icon

Keep up with the latest trade news.

Stay informed with up-to-date information on US and Canadian customs and international trade topics.

Explore Our Resources